SCHEDULE: Deep Track Capital Exits Akero Therapeutics Stake

Deep Track Capital and its affiliates have reported a 0% beneficial ownership in Akero Therapeutics, Inc., indicating a full divestment or reduction below the reporting threshold.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin filed an Amendment No. 1 to Schedule 13G.
• The filing reports 0% beneficial ownership of Akero Therapeutics, Inc. Common Stock as of December 31, 2025.
• This indicates that the reporting persons no longer hold a reportable stake in Akero Therapeutics.
• The calculation of ownership is based on 82,316,179 Common Stock outstanding as of November 3, 2025, according to the issuer's 10-Q filed on November 7, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative development for Akero Therapeutics, as the complete divestment by a significant institutional investor like Deep Track Capital could imply a loss of confidence or a strategic shift away from the company.

Negatives

• A significant institutional investor, Deep Track Capital and its affiliates, has divested its entire reportable stake in Akero Therapeutics, Inc.

Risks

• The divestment by a significant institutional investor could signal a lack of confidence or a change in investment strategy regarding Akero Therapeutics, potentially impacting investor sentiment.

Future Outlook

No forward-looking statements or guidance are provided in this beneficial ownership filing.

Management Comments

• David Kroin, as Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and as Director for Deep Track Biotechnology Master Fund, Ltd., certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive investors, but an amendment reporting 0% ownership signifies a complete exit or reduction below the 5% threshold by a previously significant holder. This can sometimes be interpreted by the market as a signal, especially in the biotechnology sector where investor confidence and institutional backing are crucial.

Stakeholder Impact

• Shareholders may react negatively to the news of a significant institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price due to perceived loss of confidence.

Key Dates

Recommendation

The complete divestment by a significant institutional investor like Deep Track Capital, as indicated by the 0% beneficial ownership reported in this Schedule 13G Amendment, suggests a lack of conviction or a negative outlook on Akero Therapeutics. This action by a sophisticated investor could signal underlying concerns or a belief that the stock's future performance is unfavorable, prompting a 'sell' recommendation for other investors to consider reducing their exposure.

Keywords

Akero Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, beneficial ownership, divestment, institutional investor, common stock, biotechnology